A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-18

Study Completion Date

2024-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to learn what happens to the amount of enlicitide decanoate in the blood when enlicitide decanoate is given in different formulations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035)

NCT06880874

Healthy

COMPLETED PHASE1

Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects

NCT01053520

Healthy Female Subjects

COMPLETED PHASE1

A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants

NCT06477926

Healthy Volunteers

COMPLETED PHASE1

MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013)

NCT06649877

Healthy

COMPLETED PHASE1

A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants

NCT05836506

Healthy Volunteer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Enlicitide Decanoate Treatment A

Participants will receive a single dose of enlicitide decanoate formulation 1 on Day 1 on an empty stomach.

Group Type EXPERIMENTAL

Enlicitide decanoate

Intervention Type DRUG

Oral tablet

Enlicitide Decanoate Treatment B

Participants will receive a single dose of enlicitide decanoate formulation 2 on Day 1 on an empty stomach.

Group Type EXPERIMENTAL

Enlicitide decanoate

Intervention Type DRUG

Oral tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Enlicitide decanoate

Oral tablet

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MK-0616

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing.
* Medically healthy with no clinically significant medical history.